Neuroscience 77 (1), 257270 (1997)
Among these, liraglutide in the LEADER study, semaglutide in the SUSTAIN-6, albiglutide in the Harmony Outcomes, dulaglutide in the REWIND, and efpeglenatide in the AMPLITUDE-O exhibited significant beneficial effects on 3-point major adverse cardiac events (3P-MACE: death from CV disease, non-fatal myocardial infarction, and non-fatal stroke), the primary end point of each study, compared to the placebo group, respectively
We also performed real-time imaging of cAMP levels in ex vivo hindbrain slices from Gipr-Cre CAMPER reporter mice (Fig
This is particularly important for patients also taking insulin or sulfonylureas, as the risk of hypoglycaemia is already increased with these combinations
Taking these supplements may also boost mood and improve symptoms of depression
Do not exceed 2 grams per single dose